Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + liposomal mitoxantrone + cytarabine induction in young AML (single-arm phase II)
ChiCTR2600129103Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Henan Cancer Hospital. Primary endpoint: Composite Complete Remission Rate (CRc). Started Jul 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600129103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129103.